Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection

Journal of Clinical Immunology

Volumn 24, Issue 2, 2004, Pages 135-144

  Martinez Marino B ^a   Ashlock, B M ^a   Shiboski, S ^b   Hecht, F M ^a   Levy, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

CD4 cell; CD8 cell; Cellular response; HIV; IL 2

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 1842607721     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000019778.96564.26     Document Type: Article

References (48)

1. Mackewicz CE, Yang LC, Lifson JD, Levy JA: Non-cytolytic CD8 T-cell anti-HIV responses in primary infection. Lancet, 344:1671-1673, 1994
2. Levy JA: The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 22:312-316, 2001
3. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566, 1986
4. + T-cell-mediated suppression of human immunodeficiency virus replication. J Virol 72:10165-10170, 1998
5. + cells. Immunol Today 17:217-224, 1996
6. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 87:1462-1466, 1991
7. Levy JA: HIV pathogenesis and long-term survival. AIDS 7:1401-1410, 1993
8. + T cells correlates with CD4 counts and clinical stage of disease. Clin Exp Immunol 97:68-75, 1994
9. + cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci USA 98:597-602, 2001
10. Smith KA: Interleukin-2: Inception, impact, and implications. Science 240:1169-1176, 1988
11. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Jr., Falloon J, Polis MA, Walker RE, Slevens R, Salzman NP, Metcalf JA, Masur H, Lane HC: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 332:567-575, 1995
12. Davey RT, Jr., Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Fyfe G, Lane HC: Subcutaneous administration of interluekin-2 in human immunodeficiency virus type I-infected persons. J Infect Dis 175:781-789, 1997
13. Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, Borchard C, Muller K, Beckmann A, Eppner MT, Berger A, Fiedler M: Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patienis. AIDS 12:F225-F234, 1998
14. Simonelli C, Zanussi S, Sandri S, Comar M, Lucenti A, Talamini R, Bortolin MT, Giacca M, De Paoli P, Tirelli U: Concomitant therapy wilh subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 20:20-27, 1999
15. Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA: Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial. HIV Clin Trials 1:1-15, 2000
16. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, Goujard C, Rouzioux C, Maral J, Delfraissy JF, Emilie D, Aboulker JP: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial. AIDS 17:343-351, 2003
17. + lymphocyte numbers but does not enhance responses to immunization: Results of A5046s. J Infect Dis 187:320-325, 2003
18. + cell response against human immunodeficiency virus: Implications for long-term survival. Proc Natl Acad Sci USA 92:11135-11139, 1995
19. + T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 92:10985-10989, 1995
20. + T lymphocytes in interleukin-2-treated HIV-infecied patients. J Acquir Immune Defic Syndr 22:31-38, 1999
21. Pandolfi F, Pierdominici M, Marziali M, Livia Bernardi M, Antonelli G, Galati V, D'Offizi G, Aiuti F: Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol 94:153-159, 2000
22. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, Chesney M, Anderson J, Walker B, Levy J, Kahn JO: Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 16:1119-1129, 2002
23. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP: New testing strategy to deieci early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. J Am Med Assoc 280:42-48, 1998
24. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, Ng V, Hadley K: Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol 38:1113-1120, 2000
25. Castro BA, Weiss CD, Wiviott LD, Levy JA: Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol 26:2371-2376, 1988
26. Mackewicz CE, Barker E, Levy JA: Role of β-chemokines in suppressing HIV replication. Science 274:1393-1395, 1996
27. Hoffman AD, Banapour B, Levy JA: Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147:326-335, 1985
28. Ihaka R, Gentleman RR: A language for data analysis and graphics. J Comput Graphic Stat 5:299-314, 1996
29. Stata: Stata Statistical Software: Release 7.0, Reference H-P. College Station, TX, StataCorp, 2001.
30. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O: Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type I infection. J Infect Dis 175:1051-1055, 1997
31. Hoen B, Dumon B, Harzic M, Venet A, Dubeaux B, Lascoux C, Bourezane Y, Ragnaud JM, Bicart-See A, Raffi F, Beauvais L, Fleury H, Sereni D: Highly active antiretroviral treatment initiated early in the course of symptomatic priamry HIV-1 infection: Results of the ANRS 053 trial. J Infect Dis 180:1342-1346, 1999
32. Lillo FB, Ciuffreda D, Veglia F, Capiluppi B, Mastrorilli E, Vergani B, Tambussi G, Lazzarin A: Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS 13:791-796, 1999
33. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Ji X, Chaudhry MR, Yaman M, Frankel S, Heath-Chiozzi M, Leonard JM, Moore JP, Racz P, Nixon DF, Ho DD: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 179:527-537, 1999
34. Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, Musey L, Schacker T, Corey L, McElrath MJ: Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 181:121-131, 2000
35. + T lymphocytes. Proc Natl Acad Sci USA, 97:3382-3387, 2000
36. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn IO, Brander C, Goulder PJ, Levy JA, Mullins, JI, Walker BD: Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 193:169-180, 2001
37. Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M: Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV) -specitic T cell responses in primary HIV infection. J Infect Dis 187:748-757, 2003
38. Dalod M, Harzic M, Pellegrin I, Dumon B, Hoen B, Sereni D, Deschemin J-C, Levy J-P, Venet A, Gomard E: Evolution of cytotoxic T lymphocytes responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 178:61-69, 1998
39. Musey LK, Krieger JN, Hughes JP, Schacker TW, Corey L, McElrath MJ: Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 180:278-284, 1999
40. Soudeyns H, Campi G, Rizzardi GP, Lenge C, Demarest JF, Tambussi G, Lazzarin A, Kaufmann D, Casorali G, Corey L, Pantaleo G: Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-tell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood 95:1743-1751, 2000
41. Waldmann TA: The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol Today 14:264-270, 1993
42. Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, Vaccher E, Nasti G, Politi D, Barzan L, Tirelli U, De Paoli P: Immunological changes in peripheral blood an in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin Exp Immunol 116:486-492, 1999
43. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, Delbeke E: Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J Acquir Immune Defic Syndr 26:44-55, 2001
44. Dybul M, Hildago B, Chun TW, Belson M, Migueles SA, Justement JS, Herpin B, Perry C, Hallahan CW, Davey RT, Metcalf JA, Connors M, Fauci AS: Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 185:61-68, 2002
45. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD: Association between virus-specific cytotixic T-lymphocyte and helper responses in human immunodeficiency virus type I infection. J Virol 73:6715-6720, 1999
46. + anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: Loss of CASA is associated with loss of viremia. J Infect Dis 180:68-75, 1999
47. + cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 96:1030-1035, 1999
48. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R: Viral immune evasion due to persistence of activated T cells without effector funclion. J Exp Med 188:2205-2213, 1998